FDA grants approval to Samsung Bioepis’ Ospomyv and Xbryk, expanding access to biosimilar treatments for osteoporosis and cancer-related bone loss

The U.S. Food and Drug Administration (FDA) has approved Ospomyv™ and Xbryk™, two biosimilars developed by Samsung Bioepis Co., Ltd., referencing Prolia and Xgeva, respectively. ... Read More